Literature DB >> 20047470

LIMK1 and LIMK2 are important for metastatic behavior and tumor cell-induced angiogenesis of pancreatic cancer cells.

Danielle H Vlecken1, Christoph P Bagowski.   

Abstract

The two LIM kinases (LIMKs) LIMK1 and LIMK2 are members of the PDZ/LIM family. These serine/threonine protein kinases are involved in actin cytoskeleton reorganization through phosphorylation and inactivation of ADF/cofilin. Different subcellular localizations of LIMK1 and LIMK2 suggest different functions. LIMK1 is implicated in microtubule disassembly in endothelial- and cancer cells, whereas LIMK2 plays a role in cell cycle progression. To compare the role of the two LIMKs in cancer-related processes, we used a cell-based in vitro migration assay, as well as two zebrafish xenograft assays. We analyzed here the metastatic behavior and tumor cell-induced neovascularization of pancreatic cancer cells in which both LIMK genes were silenced by siRNAs. Both LIMK1 and LIMK2 single knock down led to a reduction of invasion and metastatic behavior in the zebrafish xenograft metastasis assay. Interestingly, the double knock down completely blocked invasion and formation of micrometastasis in vivo. Moreover, in the zebrafish xenograft angiogenesis assay, we observed a reduction of pancreatic cancer cell-induced angiogenesis for both the LIMK1 and LIMK2 knockdowns. Our results demonstrate similar functions for the two LIMKs in pancreatic cancer cells and suggest an important role for both LIMK1 and LIMK2 in tumor progression and metastasis formation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20047470     DOI: 10.1089/zeb.2009.0602

Source DB:  PubMed          Journal:  Zebrafish        ISSN: 1545-8547            Impact factor:   1.985


  40 in total

1.  Role of cellular cytoskeleton in epithelial-mesenchymal transition process during cancer progression.

Authors:  B O Sun; Yantian Fang; Zhenyang Li; Zongyou Chen; Jianbin Xiang
Journal:  Biomed Rep       Date:  2015-07-27

2.  Molecular pathways: targeting the kinase effectors of RHO-family GTPases.

Authors:  Tatiana Y Prudnikova; Sonali J Rawat; Jonathan Chernoff
Journal:  Clin Cancer Res       Date:  2014-10-21       Impact factor: 12.531

3.  Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma.

Authors:  Jason P Wong; Timothy J Stuhlmiller; Louise C Giffin; Carolina Lin; Rachele Bigi; Jichen Zhao; Weihe Zhang; Ariana G Bravo Cruz; Steven I Park; H Shelton Earp; Dirk P Dittmer; Stephen V Frye; Xiaodong Wang; Gary L Johnson; Blossom Damania
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-25       Impact factor: 11.205

4.  Identification of LIMK2 as a therapeutic target in castration resistant prostate cancer.

Authors:  Kumar Nikhil; Lei Chang; Keith Viccaro; Max Jacobsen; Callista McGuire; Shakti R Satapathy; Michael Tandiary; Meaghan M Broman; Gregory Cresswell; Yizhou J He; George E Sandusky; Timothy L Ratliff; Dipanjan Chowdhury; Kavita Shah
Journal:  Cancer Lett       Date:  2019-02-01       Impact factor: 8.679

Review 5.  Novel anti-HIV therapeutics targeting chemokine receptors and actin regulatory pathways.

Authors:  Mark Spear; Jia Guo; Yuntao Wu
Journal:  Immunol Rev       Date:  2013-11       Impact factor: 12.988

6.  Trailblazing LIM kinases take the lead in collective tumor cell invasion.

Authors:  Diane Crighton; Michael F Olson
Journal:  Bioarchitecture       Date:  2011-01

7.  Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors.

Authors:  Lifang Xie; Michelle Kassner; Ruben M Munoz; Qiang Q Que; Jeff Kiefer; Yu Zhao; Spyro Mousses; Hongwei H Yin; Daniel D Von Hoff; Haiyong Han
Journal:  Biochem Pharmacol       Date:  2011-11-15       Impact factor: 5.858

8.  Afzelin exhibits anti-cancer activity against androgen-sensitive LNCaP and androgen-independent PC-3 prostate cancer cells through the inhibition of LIM domain kinase 1.

Authors:  Kai-Chang Zhu; Jian-Mei Sun; Jian-Guo Shen; Ji-Zhong Jin; Feng Liu; Xiao-Lin Xu; Lin Chen; Lin-Tao Liu; Jia-Ju Lv
Journal:  Oncol Lett       Date:  2015-08-18       Impact factor: 2.967

Review 9.  Emergence of zebrafish models in oncology for validating novel anticancer drug targets and nanomaterials.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Drug Discov Today       Date:  2012-08-10       Impact factor: 7.851

10.  Repression of choroidal neovascularization through actin cytoskeleton pathways by microRNA-24.

Authors:  Qinbo Zhou; Chastain Anderson; Hongmei Zhang; Xinyu Li; Fiona Inglis; Ashwath Jayagopal; Shusheng Wang
Journal:  Mol Ther       Date:  2013-10-17       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.